REPLIMUNE GROUP INC (REPL) Stock News
NASDAQ:REPL - Nasdaq - US76029N1063 - Common Stock - Currency: USD
REPL Latest News, Press Relases and Analysis
Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for priority...
Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
Tesla, ON Semiconductor And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WOBURN, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development...
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WOBURN, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development...
Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference
WOBURN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development...
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma
PDUFA action date of July 22, 2025, with priority review
Replimune Announces Pricing of Upsized Public Offering
BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of...
Replimune Announces Proposed Public Offering
WOBURN, Mass., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development...
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Replimune Announces Pricing of Upsized Public Offering
Replimune Announces Proposed Public Offering
Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update
Completed Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) and remain on track to submit a BLA for RP1 plus...
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WOBURN, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development...
Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Late-breaking abstract featuring IGNYTE clinical trial data, including subgroup and initial biomarker analyses, selected for oral presentation Data from...
Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway
WOBURN, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development...
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WOBURN, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development...
Replimune to Present at Two Upcoming Investor Conferences
WOBURN, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development...
Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024
Aligned with FDA on accelerated approval pathway for RP1 in anti-PD1 failed melanoma...
Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update
Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)
Oral presentation highlighting IGNYTE primary analysis data shows anti-tumor activity across all subgroups with injected and non-injected lesions...
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma
Confirmatory Phase 3 Trial to assess efficacy and safety of the investigational oncolytic immunotherapy, RP1 (vusolimogene oderparepvec) in combination...
Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024
Data from the IGNYTE primary analysis shows clinically meaningful activity across all subgroups, including those who had received prior anti-PD1 and...